anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemical and pharmaceutical industry; production of pharmaceuticals for prophylaxis or treatment of hypercholestemy. SUBSTANCE: tablet contains finely-dispersed CHOLESTEROL hydrochloride, povidon, colloidal silicon dioxide and magnesium stearate taken in proprietary weight ratio. Tablet has the following physical parameters: hardness, 40-75 SCV units; brittleness, 0-0.1%/15 min; weight, 1017-1079 mg; disintegration time, less than 5 min; thickness, 5.08-8.64. Tablet is produced by method involving: mixing povidon and finely-dispersed CHOLESTEROL hydrochloride, drying the mixture and its homogenization, followed by adding to it colloidal silicon dioxide and magnesium stearate. Proposed tablets are harder than known ones but easily disintegrated. EFFECT: higher efficiency. 16 cl, 3 tbl
Postoperative rhabdomyolysis is a significant complication that can arise from prolonged surgery, causing potential harm to the kidneys and leading to acute renal failure. Despite its importance, the incidence of rhabdomyolysis following ear reconstruction surgery remains undocumented in the literature. In this report, we present a case study of a male patient in his forties who underwent otoplasty for ear reconstruction after the amputation of his right ear due to a physical assault. The surgery lasted for 8 h under general anesthesia, and unfortunately, the patient developed postoperative rhabdomyolysis, which resulted in severe renal failure and ultimately an unrecoverable cardiac arrest, leading to his death. The autopsy findings indicated no identifiable lesions except for organ congestion, while histopathology revealed acute tubular necrosis of the kidney and muscle rhabdomyolysis. Previous literature has explored the association between surgical duration, location, and rhabdomyolysis, underscoring that this condition is an infrequent yet preventable consequence of prolonged surgery. The co-occurrence of rhabdomyolysis and acute renal injury in this case suggests the presence of comorbidity, emphasizing the need for prompt action to mitigate the negative consequences of rhabdomyolysis. Awareness and early intervention are crucial in preventing and managing this condition effectively.
FIELD: medicine. ^ SUBSTANCE: invention discovers the application of a liquid composition for preparing a drug for open wounds and burns. The composition contains a component specified in the salts containing An+ cations and anions formed by halogen oxides according to general formula [OmX] - where A represents lithium, sodium, potassium or calcium, X represents halogen atom, m=1, n=1 or 2, a component specified in the oxygen donors, and a liquid binding agent. In addition, the composition can contain a stabilising agent for the oxygen donors. Said composition promotes tissue cell growth in a wound, thereby providing better tissue regeneration and wound healing. ^ EFFECT: invention also concerns a wound bandage containing said composition. ^ 28 cl, 3 tbl, 5 ex
PURPOSE: A composition containing Phellinus Linteus extract and Platycodon grandiflorus A. DC. Candolle extract is provided to treat bronchial diseases. CONSTITUTION: A composition for treating asthma contains Platycodon grandiflorus A. DC. Candolle and Phellinus Linteus extract as an active ingredient. The Platycodon grandiflorus A. DC. Candolle is prepared by pre-drying, steaming, and drying 6-15 times. The Phellinus Linteus extract is obtained by pulverizing Phellinus Linteus and adding 15-20 times water. A health food for treating asthma contains the composition for treating asthma.
NEW MATERIAL:A compound shown by formula I (R<1> is H, 2-6C alkyl or 2-6C acyl; R<2> is H or 1-3C alkyl; compound wherein both R<1> and R<2> are H is omitted). EXAMPLE:5-Ethyl-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indole. USE:Having diuretic action, heart suppressing action, relaxing action on smooth muscle and sleep prolonging action, useful as a remedy for circulatory diseases, remedy for alimentary diseases and psychotropic agent. PREPARATION:A 4-cyanoindole derivative shown by formula II is hydrolyzed with a base such as triton B and subjected to ring closure to produce a compound shown by formula III. Then this compound is reduced with a reducing agent such as lithium aluminum hydride. The starting raw material shown by formula II is produced by reacting a compound shown by formula IV with a nitroalkane, hydrogenating and reducing the reaction product.
REMICADE has been associated with hypersensitivity reactions that vary in their time of onset and required hospitalization in some cases. Most hypersensitivity reactions (including anaphylaxis, urticaria, dyspnea, and/or hypotension), have occurred during or within 2 hours of REMICADE infusion. 

However, in some cases, serum sickness-like reactions have been observed in patients after initial REMICADE therapy (i.e., as early as after the second dose), and when REMICADE therapy was reinstituted following an extended period without REMICADE treatment. Symptoms associated with these reactions include fever, rash, headache, sore throat, myalgias, polyarthralgias, hand and facial edema and/or dysphagia. These reactions were associated with a marked increase in antibodies to infliximab, loss of detectable serum concentrations of infliximab, and possible loss of drug efficacy. 

REMICADE should be discontinued for severe hypersensitivity reactions. Medications for the treatment of hypersensitivity reactions (e.g., acetaminophen, antihistamines, corticosteroids and/or epinephrine) should be available for immediate use in the event of a reaction [see Dosage and Administration (2.10) and Adverse Reactions (6.1)].

In RA, CD and Ps clinical trials, re-administration of REMICADE after a period of no treatment resulted in a higher incidence of infusion reactions relative to regular maintenance treatment [see Adverse Reactions (6.1)]. In general, the benefit-risk of re-administration of REMICADE after a period of no-treatment, especially as a re-induction regimen given at weeks 0, 2 and 6, should be carefully considered. In the case where REMICADE maintenance therapy for Ps is interrupted, REMICADE should be reinitiated as a single dose followed by maintenance therapy.
PURPOSE: A method for extracting antibacterial active ingredients from Zingiber officinale Roscoe by supercritical extraction is provided to effectively obtain the antibacterial antioxidative ingredients. CONSTITUTION: A method for antibacterial active ingredients against Listeria sp. comprises a step of supercritical extraction of Zingiber officinale Roscoe at 200-300 bar and 30-40 Deg. C. Zingiber officinale Roscoe includes Zingiberis Rhizoma crudus, Curcumae longae Rhizoma, or Zingiber moiga Roscoe. The Listeria sp. includes L.monocytogenes.
In endometriosis, the tissues similar to the endometrial tissue attaches outside the uterine cavity, causing inflammation and fibrosis. The retrograde menstruation theory is the most plausible mechanism, though the detailed pathogenesis remains unclear. Our observations suggest that endometriosis-like lesions occur more often at sites of ovarian excision causing bleeding in mouse models. Additionally, prostaglandin E2 (PGE2) and thrombin, a protease-activated receptor (PAR) agonist in menstrual blood exacerbate inflammation in these lesions. Focusing on the hypoxic conditions of menstrual blood, we investigated the effects of PGE2/thrombin on inflammation and fibrosis using primary cultured endometrial stromal cells (ESCs) and glandular epithelial cells (EECs) under low oxygen conditions. Chemokine CXCL12 secreted by endometrial stromal cells under hypoxia acts on CXCR4 receptors on glandular epithelial cells, inducing epithelial-mesenchymal transition (EMT), suggesting a possible role in endometriosis progression. RNA-seq analysis of PGE2/thrombin effects on endometrial stromal cells revealed activation of the transforming growth factor (TGF)-β pathway, particularly increased production and secretion of activin A, a member of the TGFβ family. Activin A, via increased connective tissue growth factor (CTGF) expression, promotes differentiation of endometrial stromal cells from fibroblast-like to myofibroblast transdifferentiation (FMT) of ESCs. In conclusion, targeting the CXCL12/CXCR4 and activin A/CTGF signaling pathways holds promise for improving fibrosis in endometriosis lesions.
The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LTα, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LTα−/− Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LTα expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha.
BACKGROUND: Myocardial ischemia-reperfusion injury (MIRI) refers to severe damage to the ischemic myocardium following the restoration of blood flow, and it is a major complication of reperfusion therapy for myocardial infarction. Notably, drugs such as metoprolol have been utilized to reduce ischemia-reperfusion injury. Tanshinone IIA is a major constituent extracted from Salvia miltiorrhiza Bunge. Recently, tanshinone IIA has been studied extensively in animal models for controlling MIRI. Therefore, we conducted a meta-analysis on the application of tanshinone IIA in rat models with MIRI to evaluate the therapeutic effects of tanshinone IIA.
METHODS: A comprehensive search was conducted across PubMed, Web of Science, Embase, the Cochrane Library, the China National Knowledge Infrastructure database, the Wanfang database, and the Chinese Scientific Journal Database to gather studies on tanshinone IIA intervention in rat models with MIRI.We employed SYRCLE's risk of bias tool to assess study quality. The primary outcome indicators were superoxide dismutase (SOD) and malondialdehyde (MDA). Myocardial infarction area was a secondary outcome indicator. This study was registered at PROSPERO (registration number CRD 42022344447).
RESULTS: According to the inclusion and exclusion criteria, 15 eligible studies were selected from 295 initially identified studies. In rat models with MIRI, tanshinone IIA significantly increased SOD levels while reducing MDA levels and myocardial infarction area. Moreover, the duration of myocardial ischemia influenced the effectiveness of tanshinone IIA. However, additional high-quality research studies are needed to establish the efficacy and definitive guidelines for the use of tanshinone IIA. Animal studies demonstrated that tanshinone IIA exerted a significant therapeutic effect when the ischemia duration was less than 40 minutes. Tanshinone IIA was found to be more effective when administered via intravenous, intraperitoneal, and intragastric routes at doses above 5 mg/kg. Additionally, treatment with tanshinone IIA at all stages-prior to myocardial ischemia, after ischemia but before reperfusion, prior to ischemia and after reperfusion, and after reperfusion-showed satisfactory results.
CONCLUSIONS: Tanshinone IIA enhanced SOD activity and reduced MDA levels, thereby ameliorating oxidative stress damage during MIRI. Additionally, it reduced the myocardial infarction area, indicating its effectiveness in mitigating MIRI-induced damage in rats and demonstrating a myocardial protective effect. These findings contribute valuable insights for developing MIRI treatment strategies.
Background: Autochthonous human West Nile virus (WNV) infections were notified in the infectious disease surveillance system in Germany in 2018 for the first time and every year since then. Since clinically apparent infections are infrequent, we conducted two studies to investigate subclinical infections of this emerging disease in Germany in 2019 to detect infections not visible to surveillance based on symptomatic infections: limited-scope blood donor testing and a serosurvey among employees at two Berlin zoos with a history of demonstrated WNV infections in animals. Methods: For the zoo study, employees of the two zoos in Berlin were invited to participate in the study in late 2019. Blood samples were drawn and tested for the presence of antibodies (immunoglobulin M [IgM] and immunoglobulin G [IgG]) against WNV, and two other flaviviruses present in Germany: Usutu virus and Tick-borne encephalitis virus (TBEV). For the study in blood donors, four blood establishments with collection sites in regions with documented WNV-infected animals in 2018 and 2019 participated in the study. All donations in these regions were tested for WNV genome from July to November 2019. Results: In the enzyme-linked immunosorbent assay, none of the 70 tested zoo employees were WNV IgM-positive, 8 were WNV IgG-positive, additional 2 participants had equivocal results. All 10 were negative in the virus neutralization test (VNT) for WNV, but positive in the VNT for TBEV. None of the 4273 samples from blood donors tested in areas with WNV-infected animals was positive for WNV-RNA. Conclusion: Our results indicate that WNV circulation in Germany, though clearly documented in animals in 2019, apparently affected very few humans. Still areas with WNV-positive animals remain risk areas for human infection as well.
The effects of hypocapnia on the postural system have not previously been adequately investigated. The specific aim of this study is to evaluate the effects of hypocapnia on postural standing balance using the sharpened Romberg test (SRT). There is very little research in this area, even though there is significant clinical relevance, ranging from individuals with conditions affecting ventilation (respiratory conditions, cardiac conditions, concussions, medications, post-surgical states requiring ventilatory support etc). The design of the experiment consists of testing healthy subjects and measuring their standing balance with SRT before and after they deliberately lower their carbon dioxide levels by increased ventilation over 2min. End-tidal CO2 (ETCO2) will be used to estimate the blood carbon dioxide level during the experimental procedures. ETCO2 will be measured using the Masimo, Emma Capnometer device. The device is a measurement tool that reads the end tidal carbon dioxide level on its display. The results will then be compared to the normal pre-hypocapnic SRT to assess how hypocapnia affects standing balance.
Tumor angiogenesis is associated with invasiveness and the metastatic potential of various cancers. Vascular endothelial growth factor (VEGF), the most potent and specific angiogenic factor, regulates normal and pathologic angiogenesis. The increased expression of VEGF has been correlated with metastases, recurrence and poor prognosis in many cancers. It has been shown the VEGF is involved in osteolysis in women with bone metastases. ZACTIMA is an agent which targets VEGF. ZACTIMA is a new agent with novel method of action - it is a VEGF inhibitor, epidermal growth factor (EGFR) inhibitor, tyrosine kinase inhibitor, as well as a potential RET kinase activity inhibitor.

In summary, women with bone only, or bone predominant, metastatic breast cancer is an ideal group to study anti-angiogenic therapies where angiogenesis could be a major factor in tumor progression and where anti-angiogenic treatment with agents like ZACTIMA could be more effective.
The invention describes a novel method for determining the mass of vital tumor cells of xenotransplants in animal models. Cells altered by genetic engineering which form a tumor after transplantation synthesize an excreted reporter gene. This is shown by way of example for a secreted form of human placenta-specific, alkaline phosphate (SEAP). The latter can be demonstrated in the serum of test animals or in culture supernatants. The activity of SEAP in the serum correlates with the number of vital tumor cells in the animal and can be measured prior to the formation of a palpable tumor. The invention shows the use of cell lines altered by genetic engineering in such a manner in subcutaneous and orthotopic tumor models. Dicistronic, eukaryotic expression vectors are used for the stable transfection of the mammalian cell lines or tumor cells used. These vectors contain, under the control of a constitutive or inducible promotor element, the gene coding for SEAP, coupled with a second gene. This latter gene codes e.g. for a receptor tyrosine kinase such as erbB2/HER2 which transforms during overexpression.
Patients with concurrent intrahepatic cholangiocarcinoma (ICC) and hepatolithiasis generally have poor prognoses. Hepatolithiasis is once considered the primary cause of ICC, although recent insights indicate that bacteria in the occurrence of hepatolithiasis can promote the progression of ICC. By constructing in vitro and in vivo ICC models and patient-derived organoids (PDOs), it is shown that Escherichia coli induces the production of a novel RNA, circGLIS3 (cGLIS3), which promotes tumor growth. cGLIS3 binds to hnRNPA1 and G3BP1, resulting in the assembly of stress granules (SGs) and suppression of hnRNPA1 and G3BP1 ubiquitination. Consequently, the IKKα mRNA is blocked in SGs, decreasing the production of IKKα and activating the NF-κB pathway, which finally results in chemoresistance and produces metastatic phenotypes of ICC. This study shows that a combination of Icaritin (ICA) and gemcitabine plus cisplatin (GP) chemotherapy can be a promising treatment strategy for ICC.
Immune cell activation triggers signaling cascades leading to transcriptional reprogramming, but also strongly impacts on the cell's metabolic activity to provide energy and biomolecules for inflammatory and proliferative responses. Macrophages activated by microbial pathogen-associated molecular patterns and cytokines upregulate expression of the enzyme ACOD1 that generates the immune-metabolite itaconate by decarboxylation of the TCA cycle metabolite cis-aconitate. Itaconate has anti-microbial as well as immunomodulatory activities, which makes it attractive as endogenous effector metabolite fighting infection and restraining inflammation. Here, we first summarize the pathways and stimuli inducing ACOD1 expression in macrophages. The focus of the review then lies on the mechanisms by which itaconate, and its synthetic derivatives and endogenous isomers, modulate immune cell signaling and metabolic pathways. Multiple targets have been revealed, from inhibition of enzymes to the post-translational modification of many proteins at cysteine or lysine residues. The modulation of signaling proteins like STING, SYK, JAK1, RIPK3 and KEAP1, transcription regulators (e.g. Tet2, TFEB) and inflammasome components (NLRP3, GSDMD) provides a biochemical basis for the immune-regulatory effects of the ACOD1-itaconate pathway. While the field has intensely studied control of macrophages by itaconate in infection and inflammation models, neutrophils have now entered the scene as producers and cellular targets of itaconate. Furthermore, regulation of adaptive immune responses by endogenous itaconate, as well as by exogenously added itaconate and derivatives, can be mediated by direct and indirect effects on T cells and antigen-presenting cells, respectively. Taken together, research in ACOD1-itaconate to date has revealed its relevance in diverse immune cell signaling pathways, which now provides opportunities for potential therapeutic or preventive manipulation of host defense and inflammation.
917,545. Master and slave manipulators. LUCAS (INDUSTRIES) Ltd., JOSEPH. March 13, 1961 [March 15, 1960], No. 9058/60. Class 39 (4). A manipulator comprises a handle end having a pivoted arm 5 coupled by a pin-and-slot arrangement 8, 7 to the piston rod 9 of a master cylinder 10, the cylinder 10 being connected to a slave cylinder 13 through an hydraulic circuit including servo mechanism 30, Fig. 2. The slave piston controls a toothed rack 14 operating toothed segments 15, 16 connected to arms 17, 18 pivoted to jaws 19, 20. The arms 17, 18 and links 21, 22 maintain the jaw faces parallel to each other and springs 24, 25 return the jaws to their open position. The handle and jaws are carried at opposite ends of a rod 61 universally mounted in a support 62. The servo mechanism 30, which ensures that a magnified pressure is exerted by the slave piston relative to the pressure applied to the master piston, comprises a body 31 having a stepped piston 33 biased by a spring 34 in a stepped bore 32, the larger end of the bore being connected through an inlet 35 to the master cylinder 10. The smaller end of the bore 32 is connected to a further bore 36 having an outlet 37 connected to the slave cylinder 13, the bore 36 containing a piston 38 biased by a spring 39. A conical seating in the piston 38 receives the stem 40 of a piston 41 biased by a spring 43 in a cylinder 42 connected at both ends to a valve chamber 44. A T- shaped valve member 45 having a stem engaging a recess 46 in the piston 33 is urged by a bowed spring to close ports 47, 48 but is rockable by the piston so as to uncover either one of them. Port 48 is connected to a compressed air supply. When the master piston is actuated hydraulic fluid is forced past the sealing in piston 38 into the bore 36 and thence to the slave cylinder through outlet 37. The pressure at the inlet 35 is also applied to both ends of the piston 33 which moves to the right owing to the different areas of its ends whereby valve 45 is rocked to close port 47 and open port 48. Compressed air is thus applied to the left-hand end of cylinder 42 to move piston 41 which in turn moves piston 38 to increase the pressure in bore 36 and hence also in the slave cylinder. The increased pressure also acts on the smaller end of the piston 33 which rocks to close the port 48. Since both ports 47, 48 are closed the system remains in equilibrium. If the pressure in the master cylinder is increased the mechanism acts to admit more compressed air through the port 48 which opens and the pressure in the slave cylinder is increased. If the master cylinder pressure is reduced the valve 45 rocks to open the 47 and connect the left-hand end of the cylinder 42 to atmosphere through exhaust passage 49. Stop cocks 11, 12, 28, 29 permit the mechanism 30 to be cut out and a direct connection to be established between the cylinders 10, 13. In a modification (Fig. 3, not shown), a further servo mechanism is provided to control opening of the jaws and the springs 24, 25 may be omitted. The Provisional Specification refers to Specification 786,524.